2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-149533
    α-Glucosidase-IN-34 98%
    α-Glucosidase-IN-34 (compound 7f) is a potent α-glucosidase inhibitor (IC50: 2.90 μM) and can be used in the study of type 2 diabetes and hyperglycemia.
    α-Glucosidase-IN-34
  • HY-149545
    1,3-Palmitin-2-docosahexaenoin 214038-32-1 98%
    1,3-Palmitin-2-docosahexaenoin (1,3-Dipalmitoyl-2-docosahexaenoyl glycerol) is the isomer of triacylglycerol (TAG), in which docosahexaenoic acid (DHA) is located at the β position (sn-2) of the glycerol backbone. 1,3-Palmitin-2-docosahexaenoin inhibits fatty acid synthase and cholesterol metabolism enzymes, activates carnitine palmitoyltransferase (CPT) in liver mitochondria and promotes β-oxidation of fatty acids. 1,3-Palmitin-2-docosahexaenoin exhibits lipid metabolism regulating activity.
    1,3-Palmitin-2-docosahexaenoin
  • HY-149550
    1,2-Eucin(13Z)-olein 675876-04-7 98%
    1,2-Eucin(13Z)-olein (compound 48) is a triacylglycerol that contains palmitic acid,? oleic acid, and arachidonic acid .
    1,2-Eucin(13Z)-olein
  • HY-149557
    α-Amylase/α-Glucosidase-IN-5 98%
    α-Amylase/α-Glucosidase-IN-5 (compound 4l) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC50s of 5.96 μM and 1.62 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity.
    α-Amylase/α-Glucosidase-IN-5
  • HY-149579
    α-Glucosidase-IN-36 3025234-94-7 98%
    α-Glucosidase-IN-36 (compound 5g) is a potent α-glucosidase inhibitor, with an IC50 of 6.69 ± 0.18 μM, Ki and Kis of 1.65 μM and 4.54 μM, respectively. α-Glucosidase-IN-36 may inhibit α-glucosidase activity by binding with its active site as well as changing the secondary structure of α-glucosidase. α-Glucosidase-IN-36 can be used for type 2 diabetes mellitus (T2DM) research.
    α-Glucosidase-IN-36
  • HY-149593
    VU0506013 1207036-87-0
    VU0506013 is a selective positive allosteric modulator of Y4R (KB = 34.9 nM). VU0506013 can be used in the development of anti-obesity agents targeting Y4R.
    VU0506013
  • HY-149594
    CL-Pa 98%
    CL-Pa is a chemiluminescent probe suitable for detection of urinary Vanin-1. CL-Pa can be used to detect drug-induced acute kidney injury (AKI) through urinalysis.
    CL-Pa
  • HY-149596
    PTZ-LD 2231747-49-0 98%
    PTZ-LD is a phenothiazine (HY-Y0055)-based fluorescent probe for lipid droplets (LDs) detection. PTZ-LD is apparently emissive in LDs with high specificity. (Ex/Em=488/570-620 nm). PTZ-LD can be used for diabetic cataract (DC) research.
    PTZ-LD
  • HY-149668
    α-Glucosidase-IN-41 3012673-89-8 98%
    α-Glucosidase-IN-41 (compound 5o) is a potent α-glucosidase inhibitor. α-Glucosidase-IN-41 can arise the changed secondary structure of α-Glu to hinder enzyme catalytic activity. α-Glucosidase-IN-41 can be used for diabetes mellitus research.
    α-Glucosidase-IN-41
  • HY-149676
    α-Glucosidase-IN-42 98%
    α-Glucosidase-IN-42 (Compound 26) is a 9-O-berberrubine carboxylate derivative. α-Glucosidase-IN-42 has potent α-glucosidase inhibitory activities with an IC50 value in the range of 1.61 μM. α-Glucosidase-IN-42 can be used for the research of antidiabetic.
    α-Glucosidase-IN-42
  • HY-149719
    Ferroptosis-IN-4 2798922-35-5 98%
    Ferroptosis-IN-4 (compound 6k) is a ferroptosis inhibitor with EC50 value of 20 μM. Ferroptosis-IN-4 has no obvious cytotoxicity. Ferroptosis-IN-4 has a protective effect in glycerol-induced RM-AKI mice with alleviating kidney dysfunction.
    Ferroptosis-IN-4
  • HY-149727
    β2AR agonist 2 98%
    β2AR agonist 2(compound 8a) is a β2 -Adrenergic receptor (β2AR) agonist. β2AR agonist 2 is a saturated nitrogen ring compound containing 4- to 7-membered heterocycle. β2AR agonist 2 has a chiral structure (the -R form) by carrying carbon containing the essential hydroxyl, thereby enhancing cellular glucose uptake (GU) activity and significantly stimulating glucose uptake by skeletal muscle cells. β2AR agonist 2 can be used in the study of Type 2 Diabetes (T2D).
    β2AR agonist 2
  • HY-149728
    β2AR agonist 3 2304455-74-9 98%
    β2AR agonist 3 (compound 9a) is a β2-adrenergic receptor (β2AR) agonist. β2AR agonist 3 can be used for type 2 diabetes research.
    β2AR agonist 3
  • HY-149770
    CYP4A11/CYP4F2-IN-2 2280834-99-1 98%
    CYP4A11/CYP4F2-IN-2 (compound 15) is an orally available inhibitor of CYP4A11/4F2 with IC50s of 120 nM and 220 nM, respectively. CYP4A11/CYP4F2-IN-2 inhibits 20-HETE production in rat kidney and has potential inhibitory effects on diabetic nephropathy and autosomal dominant polycystic kidney disease.
    CYP4A11/CYP4F2-IN-2
  • HY-149802
    SLC26A3-IN-1 307552-53-0 98%
    SLC26A3-IN-1 is an inhibitor of anion exchanger protein SLC26A3 (IC50=340 nM). SLC26A3 belongs to solute carrier (SLC) proteins, and the SLC26 family. SLC26 family has broad anion specificity for chloride, bicarbonate, sulfate and oxalate. SLC26A3 down-regulates in adenoma, DRA, involves in in intestinal absorption of chloride and oxalate. The loss of SLC26A3 function mutations is associated with chloride-losing diarrhea.
    SLC26A3-IN-1
  • HY-149808
    TGR5 agonist 2 3027426-06-5 98%
    TGR5 agonist 2 (compound 19) is a potent TGR5 agonist with an EC50 value of 0.27 µM.
    TGR5 agonist 2
  • HY-149833
    ERRγ inverse agonist 2 324022-01-7 98%
    ERRγ inverse agonist 2 (compound 19) is a potent and selective ERRγ inverse agonist with a Kd value of 6.5 μM. ERRγ inverse agonist 2 inhibits the expression of hepcidin, fibrinogen and gluconeogenic genes. ERRγ inverse agonist 2 has antimicrobial, anti-coagulant and antidiabetic activities.
    ERRγ inverse agonist 2
  • HY-149893
    MGAT2-IN-4 1841424-92-7 98%
    MGAT2-IN-4 (compound 33) is an inhibitor of monoacylglycerol transferase 2 (MGAT2), with liver metabolic stability. MGAT2-IN-4 can be used for research on obesity, diabetes and non-alcoholic steatohepatitis (NASH).
    MGAT2-IN-4
  • HY-149973
    α-Amylase-IN-4 98%
    α-Amylase-IN-4 (Compd 10y) show maximum inhibition of amylase activity with IC50 value 17.83 ± 0.14 μg/mL.
    α-Amylase-IN-4
  • HY-150052
    Plasma kallikrein-IN-3 1357950-47-0 98%
    Plasma kallikrein-IN-3 is a plasma kallikrein inhibitor (IC50: 0.15 μM). Plasma kallikrein-IN-3 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research.
    Plasma kallikrein-IN-3
Cat. No. Product Name / Synonyms Application Reactivity